纳武利尤单抗联合伊匹木单抗治疗日本晚期黑色素瘤患者的疗效与安全性:一项开放标签、单臂、多中心II期研究
这项多中心单臂II期研究纳入30例未经治疗的日本晚期黑色素瘤患者,接受纳武利尤单抗(1 mg/kg)联合伊匹木单抗(3 mg/kg)每3周共4次,随后纳武利尤单抗(3 mg/kg)每2周一次。中心评估客观缓解率为43.3%(95%CI:25.5, 62.6),中位随访14.1个月时中位OS和中心评估PFS均未达到。所有患者发生治疗相关不良事件,III-IV级和严重不良事件分别见于23例(76.7%)和20例(66.7%),无治疗相关死亡。
要点
- 中心评估客观缓解率为43.3%(95%CI:25.5, 62.6),中心与局部评估一致。
- 中位随访14.1个月(范围5.2-27.7)时,中位OS和中心评估PFS均未达到。
- 所有患者发生治疗相关不良事件,III-IV级见于23例(76.7%),严重不良事件见于20例(66.7%),无治疗相关死亡。
核心结论
- 本研究证实纳武利尤单抗联合伊匹木单抗在包括罕见亚型的未经治疗日本晚期黑色素瘤患者中有效且安全。
- III-IV级不良事件发生率较高,但通过适当的医疗关注和治疗可控。
研究设计与样本
- 多中心、单臂、开放标签II期研究,纳入30例未经治疗的日本不可切除III/IV期或复发性黑色素瘤患者。
- 治疗方案为纳武利尤单抗(1 mg/kg)联合伊匹木单抗(3 mg/kg)每3周共4次,随后纳武利尤单抗(3 mg/kg)每2周一次。
- 主要终点为盲态独立中心评估的客观缓解率,次要终点包括总生存期、无进展生存期、疾病控制率和安全性。
主要发现
- 30例患者亚型分布为:黏膜型12例、非肢端皮肤型8例、肢端型7例、葡萄膜型2例、原发灶不明1例。
- 中心评估和局部评估的客观缓解率均为43.3%(95%CI:25.5, 62.6)。
- 中心评估和局部评估的疾病控制率分别为73.3%(95%CI:54.1, 87.7)和86.7%(95%CI:69.3, 96.2)。
- 中位随访14.1个月(范围5.2-27.7)时,中位OS和中心评估PFS均未达到;6、12、18和24个月OS分别为93.3%(95%CI:75.9, 98.3)、83.3%(95%CI:64.5, 92.7)、72.9%(95%CI:50.0, 86.5)和65.6%(95%CI:40.4, 82.2)。
- 所有患者发生治疗相关不良事件;III-IV级和严重不良事件分别发生于23例(76.7%)和20例(66.7%),多发生在联合治疗阶段;无治疗相关死亡。
临床怎么用
- 作者认为,纳武利尤单抗联合伊匹木单抗在未经治疗的日本晚期黑色素瘤患者(包括罕见亚型)中有效且安全。
- 作者指出,III-IV级不良事件发生率较高,但通过适当的医疗关注和治疗可控。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The aim of the study was to evaluate the efficacy and safety of nivolumab combined with ipilimumab in treatment-naïve Japanese patients with advanced melanoma. METHODS: In this multicentre, single-arm study, treatment-naïve Japanese patients with unresectable stage III/IV or recurrent melanoma received nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks for four doses, followed by biweekly doses of nivolumab (3 mg/kg). The primary end-point was centrally assessed objective response rate (ORR). Secondary end-points included overall survival (OS), progression-free survival (PFS), disease control rate and safety. RESULTS: The subtypes of the thirty patients enrolled were: 12, mucosal; eight, non-acral cutaneous; seven, acral; two, uveal and one, unknown primary melanoma. The ORR was 43.3% (95% confidence interval [CI]: 25.5, 62.6) with central and local assessment. The centrally and locally assessed disease control rate (95% CI) were 73.3% (54.1, 87.7) and 86.7% (69.3, 96.2), respectively. At the median follow-up period of 14.1 months (range 5.2-27.7), median OS and centrally assessed PFS were not reached. OS (95% CI) at 6, 12, 18 and 24 months was 93.3% (75.9, 98.3), 83.3% (64.5, 92.7), 72.9% (50.0, 86.5) and 65.6% (40.4, 82.2), respectively. Treatment-related adverse events (AEs) occurred in all patients. Grade III-IV and serious AEs occurred, mostly during the combination phase, in 23 (76.7%) and 20 (66.7%) patients, respectively. No treatment-related deaths occurred. CONCLUSIONS: This study confirmed the efficacy and safety of nivolumab plus ipilimumab in treatment-naïve Japanese patients with advanced melanoma including rare subtypes. Incidence rates for grade III-IV AEs were high but manageable with appropriate medical attention and treatment. TRIAL REGISTRATION: JapicCTI-152869.
引用
- Namikawa K, Kiyohara Y, Takenouchi T, et al. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. Eur J Cancer. 2018. PMID: 30447539. doi:10.1016/j.ejca.2018.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。